Inhibitors

NKTR-118 Oxalate; Naloxegol (Oxalate); AZ13337019 Oxalate; AZ-13337019 Oxalate; Naloxegol Oxalate(NKTR-118); Moventig; (4R,4aS,7S,7aR,12bS)-7-[2-[2-[2-[2-[2-[2-(2-Methoxyethoxy)Ethoxy]Ethoxy]Ethoxy]Ethoxy]Ethoxy]Ethoxy]-3-prop-2-enyl-1,2,4,5,6,7,7a,13-Octahydro-4,12-Methanobenzofuro[3,2-e]Isoquinoline-4a,9-diol;Oxalic acid; Movantik; 4,5Alpha-Epoxy-6Alpha-((3,6,7,12,15,18,21-Heptaoxadocosyl)oxy)-17-(prop-2-enyl)Morphinan-3,14-diol Hydrogen Ethanedioate; 4,5Alpha-Epoxy-6Alpha-[(3,6,7,12,15,18,21-Heptaoxadocosyl)oxy]-17-(prop-2-enyl)Morphinan-3,14-diol Hydrogen Ethanedioate; NKTR-118-Oxalate; NKTR-118;AZ-13337019 Oxalate; Movantik Component Naloxegol Oxalate; Naloxegol Oxalate Component OF Movantik; Morphinan-3,14-DIOL, 4,5-Epoxy-6-(3,6,9,12,15,18,21-Heptaoxadocos-1-Yloxy)-17-(2-Propen-1-YL)-, (5.Alpha.,6.Alpha.)-, Ethanedioate (1:1); Morphinan-3,14-diol, 4,5-Epoxy-6-(3,6,9,12,15,18,21-Heptaoxadocos-1-Yloxy)-17-(2-Propen-1-yl)-, (5Alpha,6Alpha)-, Ethanedioate (1:1)

960539-70-2; GSK1278863; GSK-1278863; Jesduvroq; GSK 1278863; N-((1,3-Dicyclohexylhexahydro-2,4,6-Trioxopyrimidin-5-yl)Carbonyl)Glycine; (1,3-Dicyclohexyl-2,4,6-Trioxohexahydropyrimidine-5-Carbonyl)Glycine; 2-[(1,3-Dicyclohexyl-2,4,6-Trioxo-1,3-Diazinan-5-yl)Formamido]Acetic acid; Glycine, N-((1,3-Dicyclohexylhexahydro-2,4,6-Trioxo-5-Pyrimidinyl)Carbonyl)-; Duvroq; 2-[(1,3-Dicyclohexyl-2,4,6-Trioxo-1,3-Diazinane-5-Carbonyl)Amino]Acetic acid; N-[(1,3-Dicyclohexylhexahydro-2,4,6-Trioxopyrimidin-5-yl)Carbonyl]Glycine; Duvroq (TN); Daprodustat;(1,3-Dicyclohexyl-2,4,6-Trioxohexahydropyrimidine-5-Carbonyl)Glycine

Lipaglyn; ZYH1; (S)-2-Ethoxy-3-(4-(2-(2-Methyl-5-(4-(Methylthio)Phenyl)-1H-Pyrrol-1-yl)Ethoxy)Phenyl)Propanoic acid; (2S)-2-Ethoxy-3-[4-[2-[2-Methyl-5-(4-Methylsulfanylphenyl)Pyrrol-1-yl]Ethoxy]Phenyl]Propanoic acid; Saroglitazarum; (2S)-2-Ethoxy-3-(4-(2-(2-Methyl-5-(4-(Methylsulfanyl)Phenyl)-1H-Pyrrol-1-yl(Ethoxy)Phenyl)Propanoic acid; (2S)-2-Ethoxy-3-[4-(2-{2-Methyl-5-[4-(Methylthio)Phenyl]-1H-Pyrrol-1-yl}Ethoxy)Phenyl]Propanoic acid; (S)-Alpha-Ethoxy-4-[2-[-Methyl-5-[4-(Methylthio) Phenyl]-1H-Pyrrol-1-yl]Ethoxy]Benzene-Propanoic acid; Benzenepropanoic ACID, .Alpha.-Ethoxy-4-(2-(2-Methyl-5-(4-(Methylthio)Phenyl)-1H-Pyrrol-1-YL)Ethoxy)-, (.Alpha.S)-

MK-1439; Pifeltro; Doravirine (MK-1439); 3-Chloro-5-((1-((4-Methyl-5-oxo-4,5-Dihydro-1H-1,2,4-Triazol-3-yl)Methyl)-2-oxo-4-(Trifluoromethyl)-1,2-Dihydropyridin-3-yl)oxy)Benzonitrile; 3-Chloro-5-[1-[(4-Methyl-5-oxo-1H-1,2,4-Triazol-3-yl)Methyl]-2-oxo-4-(Trifluoromethyl)Pyridin-3-yl]Oxybenzonitrile; MK1439; Mk-1439a; 3-Chloro-5-({1-[(4-Methyl-5-Oxo-4,5-Dihydro-1h-1,2,4-Triazol-3-Yl)Methyl]-2-Oxo-4-(Trifluoromethyl)-1,2-Dihydropyridin-3-Yl}oxy)Benzonitrile; Benzonitrile, 3-Chloro-5-((1-((4,5-Dihydro-4-Methyl-5-oxo-1H-1,2,4-Triazol-3-yl)Methyl)-1,2-Dihydro-2-oxo-4-(Trifluoromethyl)-3-Pyridinyl)oxy)-; 4ncg; Pifeltro (TN); 2KW; MK 1439; MK-1439(Doravirine); D0R0TS; Delstrigo Component Doravirine; Doravirine Component OF Delstrigo; 3-Chloro-5-[[1-[(4-Methyl-5-oxo-1H-1,2,4-Triazol-3-yl)Methyl]-2-oxo-4-(Trifluoromethyl)-3-Pyridyl]oxy]Benzonitrile

EGT1442; EGT-1442; THR-1442; (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-(2-Cyclopropoxyethoxy)Benzyl)Phenyl)-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-3,4,5-Triol; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-(2-Cyclopropyloxyethoxy)Phenyl]Methyl]Phenyl]-6-(Hydroxymethyl)Oxane-3,4,5-Triol; Bexagliflozin (USAN); D-Glucitol, 1,5-Anhydro-1-C-(4-Chloro-3-((4-(2-(Cyclopropyloxy)Ethoxy)Phenyl)Methyl)Phenyl)-, (1S)-; (2S,3R,4R,5S,6R)-2-(4-Chloro-3-((4-(2-(Cyclopropyloxy)Ethoxy)Phenyl)Methyl)Phenyl)-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-3,4,5-Triol; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-({4-[2-(Cyclopropyloxy)Ethoxy]Phenyl}Methyl)Phenyl]-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-3,4,5-Triol; D-Glucitol, 1,5-Anhydro-1-C-[4-Chloro-3-[[4-[2-(Cyclopropyloxy)Ethoxy]Phenyl]Methyl]Phenyl]-, (1S)-; (1S)-1,5-Anhydro-1-C-[4-Chloro-3-[[4-[2-(Cyclopropyloxy)Ethoxy]Phenyl]Methyl]Phenyl]-D-Glucitol